REG - Ovoca Bio PLC - Management Changes

Ovoca BioAnnouncement

03/03/2025 14:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250303:nRSC1377Za&default-theme=true

RNS Number : 1377Z  Ovoca Bio PLC  03 March 2025

 

Ovoca Bio PLC

3 March 2025

 

 

Ovoca Bio plc

 ("Ovoca" or the "Company")

 

Management Changes

 

Dublin, Ireland, 3 March 2025 - Ovoca Bio, a biopharmaceutical company with a
focus on women's health, is pleased to announce the appointment of Ms. Leah
O'Donovan as its Chief Financial Officer with immediate effect.

 

Ms. O'Donovan is a professional accountant with over 15 years' experience
working in the accounting and financial services industries. Prior to joining
Ovoca, she was a Senior Financial Controller at Grant Thornton, Senior
Financial Accountant at CNP Santander Insurance, and worked at such
institutions as MetLife and Maples Fiduciary Services.

 

Timothy McCutcheon, Ovoca's CEO, said "We welcome Leah to our team and look
forward to working with her for the benefit of all Ovoca stakeholders. I would
like to thank Dmitriy Nikitashenko for his service and wish him well in his
future endeavors."

 

The role of Chief Financial Officer is not a Board position at present.

 

 

End

 

For further information:

 

Ovoca Bio plc

Timothy McCutcheon (Chief Executive)

Tel +353 1 661 9819

info@ovocabio.com (mailto:info@ovocabio.com)

 

Davy (Nominated Adviser, Euronext Growth Listing Sponsor and Broker)

Ivan Murphy / Daragh O'Reilly

Tel: +353 1 679 6363

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCUOSORVOUORAR